Predicting the efficacy of new coronavirus vaccines - Are neutralising antibodies enough?
作者信息
Miller Elizabeth
机构信息
FMedSci, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Public Health, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
出版信息
EBioMedicine. 2022 May;79:104034. doi: 10.1016/j.ebiom.2022.104034. Epub 2022 Apr 27.
Abstract
摘要
相似文献
1
Predicting the efficacy of new coronavirus vaccines - Are neutralising antibodies enough?预测新型冠状病毒疫苗的疗效——中和抗体够吗？
EBioMedicine. 2022 May;79:104034. doi: 10.1016/j.ebiom.2022.104034. Epub 2022 Apr 27.
2
Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.评估新冠疫苗需要标准化的中和抗体检测。
EBioMedicine. 2021 Nov;73:103677. doi: 10.1016/j.ebiom.2021.103677. Epub 2021 Nov 3.
3
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.新型冠状病毒 ARCoV mRNA 疫苗在中国成年人中的安全性和免疫原性：一项随机、双盲、安慰剂对照、1 期临床试验。
Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24.
4
Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.二价或四价 HPV 疫苗诱导的中和抗体的持久性及其与疗效的相关性：两项随机、双盲、多中心、III 期临床试验数据的联合随访分析。
Lancet Infect Dis. 2021 Oct;21(10):1458-1468. doi: 10.1016/S1473-3099(20)30873-2. Epub 2021 May 31.
5
Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.既往感染与疫苗接种产生针对 SARS-CoV-2 变异株的中和抗体效力。
mBio. 2021 Dec 21;12(6):e0265621. doi: 10.1128/mBio.02656-21. Epub 2021 Dec 7.
6
Neutralizing Antibodies and Cytokines in Breast Milk After Coronavirus Disease 2019 (COVID-19) mRNA Vaccination.新冠肺炎（COVID-19）mRNA 疫苗接种后母乳中的中和抗体和细胞因子。
Obstet Gynecol. 2022 Feb 1;139(2):181-191. doi: 10.1097/AOG.0000000000004661.
7
Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.接种灭活疫苗后 160 天内血清抗 SARS-CoV-2 抗体的反应和持续时间。
Front Immunol. 2021 Dec 23;12:786554. doi: 10.3389/fimmu.2021.786554. eCollection 2021.
8
ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.基于ChAdOx1和MVA的中东呼吸综合征冠状病毒候选疫苗在小鼠体内引发中和抗体和细胞免疫反应。
Vaccine. 2017 Jun 27;35(30):3780-3788. doi: 10.1016/j.vaccine.2017.05.032. Epub 2017 Jun 1.
9
Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8 T cell responses.非中和抗体依赖的 SARS-CoV-2 控制与鼻内疫苗诱导的 CD8 T 细胞反应相关。
Cell Rep Med. 2022 Jan 19;3(2):100520. doi: 10.1016/j.xcrm.2022.100520. eCollection 2022 Feb 15.
10
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.辉瑞-BioNTech 新冠疫苗接种 6 个月后针对 SARS-CoV-2 关注变异株的抗体反应
Microbiol Spectr. 2022 Apr 27;10(2):e0225221. doi: 10.1128/spectrum.02252-21. Epub 2022 Mar 9.
引用本文的文献
1
Developing Correlates of Protection for Vaccines Is Needed More than Ever-Influenza, COVID-19 and RSV Infection.开发疫苗保护相关物比以往任何时候都更加重要——流感、COVID-19 和 RSV 感染。
Viruses. 2024 Oct 25;16(11):1671. doi: 10.3390/v16111671.
本文引用的文献
1
Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals.科兴新冠疫苗（CoronaVac）和BNT162b2疫苗在未感染和既往感染个体中诱导产生严重急性呼吸综合征冠状病毒2（SARS-CoV-2）中和抗体的情况。
EBioMedicine. 2022 Apr;78:103972. doi: 10.1016/j.ebiom.2022.103972. Epub 2022 Mar 30.
2
Evaluation of Immunogenicity by Pseudovirus Neutralization Assays for SARS-CoV-2 Variants after Primary and Booster Immunization.评价 SARS-CoV-2 变异株在初次免疫和加强免疫后，基于假病毒中和试验的免疫原性。
Int J Infect Dis. 2022 Apr;117:97-102. doi: 10.1016/j.ijid.2022.01.068. Epub 2022 Feb 2.
3
The T cell immune response against SARS-CoV-2.针对 SARS-CoV-2 的 T 细胞免疫应答。
Nat Immunol. 2022 Feb;23(2):186-193. doi: 10.1038/s41590-021-01122-w. Epub 2022 Feb 1.
4
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.巴西两剂科兴新冠疫苗（CoronaVac）既往接种者中异源与同源加强接种 COVID-19 疫苗（RHH-001）：一项四期、非劣效性、单盲、随机研究。
Lancet. 2022 Feb 5;399(10324):521-529. doi: 10.1016/S0140-6736(22)00094-0. Epub 2022 Jan 21.
5
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong.比较香港科兴和国药新冠疫苗的免疫原性。
Respirology. 2022 Apr;27(4):301-310. doi: 10.1111/resp.14191. Epub 2021 Nov 24.
6
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis.中和抗体滴度作为预测对 SARS-CoV-2 变异体的保护作用以及加强免疫的影响的指标：一项荟萃分析。
Lancet Microbe. 2022 Jan;3(1):e52-e61. doi: 10.1016/S2666-5247(21)00267-6. Epub 2021 Nov 15.
7
A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia.一项在 18-59 岁健康成年人中评估 SARS-CoV-2 灭活疫苗的有效性、安全性和免疫原性的 III 期、观察者盲法、随机、安慰剂对照研究：印度尼西亚的中期分析。
Vaccine. 2021 Oct 22;39(44):6520-6528. doi: 10.1016/j.vaccine.2021.09.052. Epub 2021 Sep 24.
8
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.一种灭活全病毒 SARS-CoV-2 疫苗（克尔来福）的有效性和安全性：在土耳其进行的一项双盲、随机、安慰剂对照、3 期临床试验的中期结果。
Lancet. 2021 Jul 17;398(10296):213-222. doi: 10.1016/S0140-6736(21)01429-X. Epub 2021 Jul 8.
9
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile.智利开展的灭活 SARS-CoV-2 疫苗有效性研究
N Engl J Med. 2021 Sep 2;385(10):875-884. doi: 10.1056/NEJMoa2107715. Epub 2021 Jul 7.
10
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.中和抗体水平高度预测对有症状的 SARS-CoV-2 感染的免疫保护作用。
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.
Zotero 插件